Table 2.

Selected clinical studies of oncolytic NDV in patients with cancer

NDV strain	Cancer type	Route	Outcome	Trial ID & Reference
73-T	Melanoma	Subcutaneous	55% 15-year overall survival; single-arm cohort	No trial ID [15]
ATV-NDV	Solid tumors	Intradermal	High disease control rates, with 2-year survival improvements of 20–36%	No trial ID [16]
MTH-68	High-grade glioblastomas	Intravenous	Long-term (> 5 years) survival and near-complete tumor regression in 4/4 terminal GBM patients, with no toxicity	No trial ID [96]
PV701	Advanced or recurrent tumors	Intravenous	20% ORR	NCT00081211 [93]
NDV-HUJ	Recurrent glioblastoma	Intravenous	One transient CR lasting > 3 months	NCT01174537 [97]
MEDI5395 (rNDV-GM-CSF)	Advanced solid tumors	Intravenous	10.3% ORR (PR) with manageable toxicity	NCT03889275 [50]
MEDI9253 (rNDV-IL 12)	Solid tumors	Intravenous	No efficacy data (ORR, PFS, OS) disclosed yet	NCT04613492 No reference yet
NDV-GT	Multiple advanced cancers	Intravenous ± intraperitoneal	90% disease control (1 CR + 6 PR + 11 SD) with durable responses and no serious adverse events	ChiCTR2000031980 [14]

ATV-NDV, NDV-modified autologous tumor vaccine; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; PR, partial response; CR, complete response; SD, stable disease